Effect of intravenous vitamin B12 in decreasing postoperative pai
Not Applicable
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2021/07/034615
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Female patients aged 18 to 65 years scheduled for modified radical mastectomy under
general anaesthesia.
2. Patients of American Society of Anesthesiologists(ASA) physical status I,II,III
Exclusion Criteria
1.Patients with hepatic, renal, cardiac, endocrine, psychiatric and neurological disorders.
2. Patients with history of allergy to study drug.
3. Patients who received chemotherapy prior to surgery.
4. Patients with chronic pain syndrome on treatment with long term opioids.
5. Patients who cannot understand or interpret VAS for pain assessment.
6. Patients unwilling to participate in the study.
7. Patients unable to give informed consent.
8. Pregnant and lactating women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Comparision of duration of analgesia between vitamin B12 group and control group <br/ ><br>2. Comparision of total Tramadol consumption in 24hours postoperatively between <br/ ><br>vitamin b12 group and control groupTimepoint: Total Tramadol consumption in 24hours postoperatively.
- Secondary Outcome Measures
Name Time Method 1.To assess the magnitude of pain by Visual Analogue Scale(VAS) at <br/ ><br>different points of time. <br/ ><br>2. To assess the sedation level using Ramsay sedation score <br/ ><br>3. To observe adverse events during study period.Timepoint: T1-30minutes <br/ ><br>T2-1hour <br/ ><br>T3-2hours <br/ ><br>T4-4hours <br/ ><br>T5-6hours <br/ ><br>T6-24hours